BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 567 filers reported holding BIO-TECHNE CORP in Q4 2021. The put-call ratio across all filers is 0.60 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $817 | -78.1% | 12 | -73.3% | 0.00% | -100.0% |
| Q2 2023 | $3,730 | 0.0% | 45 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $3,730 | 0.0% | 45 | 0.0% | 0.00% | 0.0% |
| Q4 2022 | $3,730 | -78.1% | 45 | -19.6% | 0.00% | -75.0% |
| Q3 2022 | $17,000 | -19.0% | 56 | -3.4% | 0.00% | -20.0% |
| Q2 2022 | $21,000 | -19.2% | 58 | -6.5% | 0.01% | -16.7% |
| Q1 2022 | $26,000 | -16.1% | 62 | +5.1% | 0.01% | -14.3% |
| Q4 2021 | $31,000 | +6.9% | 59 | 0.0% | 0.01% | -12.5% |
| Q3 2021 | $29,000 | +7.4% | 59 | 0.0% | 0.01% | +14.3% |
| Q2 2021 | $27,000 | +17.4% | 59 | -3.3% | 0.01% | 0.0% |
| Q1 2021 | $23,000 | +21.1% | 61 | 0.0% | 0.01% | +16.7% |
| Q4 2020 | $19,000 | +26.7% | 61 | 0.0% | 0.01% | +100.0% |
| Q3 2020 | $15,000 | +275.0% | 61 | +281.2% | 0.00% | +50.0% |
| Q2 2020 | $4,000 | 0.0% | 16 | -23.8% | 0.00% | 0.0% |
| Q1 2020 | $4,000 | -20.0% | 21 | 0.0% | 0.00% | 0.0% |
| Q4 2019 | $5,000 | +25.0% | 21 | +10.5% | 0.00% | +100.0% |
| Q3 2019 | $4,000 | -81.0% | 19 | -81.0% | 0.00% | -87.5% |
| Q2 2019 | $21,000 | -67.7% | 100 | -69.0% | 0.01% | -70.4% |
| Q1 2019 | $65,000 | +2066.7% | 323 | +1694.4% | 0.03% | +2600.0% |
| Q4 2018 | $3,000 | – | 18 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Blue Water Life Science Advisors, LP | 46,500 | $16,119,000 | 8.75% |
| Montanaro Asset Management Ltd | 93,950 | $32,567,000 | 4.90% |
| Jackson Square Partners, LLC | 556,157 | $192,786,000 | 4.50% |
| STONE RUN CAPITAL, LLC | 22,405 | $7,767,000 | 3.91% |
| Ownership Capital B.V. | 655,654 | $227,276,000 | 3.90% |
| Brown Capital Management | 839,587 | $291,034,000 | 3.90% |
| Sandhill Capital Partners LLC | 97,382 | $33,757,000 | 3.61% |
| DF DENT & CO INC | 684,026 | $237,111,000 | 3.34% |
| Westwind Capital | 27,946 | $9,687,000 | 3.17% |
| MAIRS & POWER INC | 655,930 | $227,371,000 | 2.72% |